Oddo BHF Asset Management Sas Takes $3.30 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Oddo BHF Asset Management Sas purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST) during the third quarter, HoldingsChannel.com reports. The fund purchased 73,091 shares of the company’s stock, valued at approximately $3,302,000.

A number of other institutional investors have also recently made changes to their positions in TWST. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $43,992,000. Point72 Asset Management L.P. boosted its holdings in shares of Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after acquiring an additional 575,080 shares during the last quarter. State Street Corp boosted its holdings in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares during the last quarter.

Insider Activity

In other news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 1.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. The trade was a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 101,787 shares of company stock worth $4,584,508 over the last quarter. Insiders own 3.92% of the company’s stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $47.90 on Friday. The stock has a market cap of $2.84 billion, a P/E ratio of -13.16 and a beta of 1.82. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The firm’s 50 day moving average price is $44.85 and its 200-day moving average price is $46.60.

Analysts Set New Price Targets

A number of research firms recently issued reports on TWST. Barclays dropped their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Scotiabank raised their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.